[go: up one dir, main page]

WO2007082742A8 - Isolated organ perfusion combination therapy of cancer - Google Patents

Isolated organ perfusion combination therapy of cancer

Info

Publication number
WO2007082742A8
WO2007082742A8 PCT/EP2007/000408 EP2007000408W WO2007082742A8 WO 2007082742 A8 WO2007082742 A8 WO 2007082742A8 EP 2007000408 W EP2007000408 W EP 2007000408W WO 2007082742 A8 WO2007082742 A8 WO 2007082742A8
Authority
WO
WIPO (PCT)
Prior art keywords
therapy
combination therapy
organ perfusion
isolated organ
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/000408
Other languages
French (fr)
Other versions
WO2007082742A1 (en
Inventor
Simon Goodman
Matthias Grell
Hagen Timo L M Ten
Alexander M M Eggermont
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/161,465 priority Critical patent/US20110165150A1/en
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to EP07702856A priority patent/EP1978991A1/en
Priority to EA200801670A priority patent/EA200801670A1/en
Priority to JP2008550686A priority patent/JP2009525957A/en
Priority to CA002637540A priority patent/CA2637540A1/en
Priority to AU2007207074A priority patent/AU2007207074B8/en
Priority to BRPI0706541-8A priority patent/BRPI0706541A2/en
Publication of WO2007082742A1 publication Critical patent/WO2007082742A1/en
Publication of WO2007082742A8 publication Critical patent/WO2007082742A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered together with said ligands, such as chemotherapeutic agents and/or radiation therapy, in isolated organ perfusion. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone.
PCT/EP2007/000408 2006-01-18 2007-01-18 Isolated organ perfusion combination therapy of cancer Ceased WO2007082742A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US12/161,465 US20110165150A1 (en) 2006-01-18 2006-01-18 Isolated organ perfusion combination therapy of cancer
EP07702856A EP1978991A1 (en) 2006-01-18 2007-01-18 Isolated organ perfusion combination therapy of cancer
EA200801670A EA200801670A1 (en) 2006-01-18 2007-01-18 COMBINED ANTI-TRACT THERAPY WITH PERFUSION OF ISOLATED ORGAN
JP2008550686A JP2009525957A (en) 2006-01-18 2007-01-18 Combined perfusion therapy for cancer
CA002637540A CA2637540A1 (en) 2006-01-18 2007-01-18 Isolated organ perfusion combination therapy of cancer
AU2007207074A AU2007207074B8 (en) 2006-01-18 2007-01-18 Isolated organ perfusion combination therapy of cancer
BRPI0706541-8A BRPI0706541A2 (en) 2006-01-18 2007-01-18 isolated cancer organ perfusion combination therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06001049.3 2006-01-18
EP06001049 2006-01-18

Publications (2)

Publication Number Publication Date
WO2007082742A1 WO2007082742A1 (en) 2007-07-26
WO2007082742A8 true WO2007082742A8 (en) 2008-05-15

Family

ID=37824910

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/000408 Ceased WO2007082742A1 (en) 2006-01-18 2007-01-18 Isolated organ perfusion combination therapy of cancer

Country Status (11)

Country Link
US (1) US20110165150A1 (en)
EP (1) EP1978991A1 (en)
JP (1) JP2009525957A (en)
KR (1) KR20080089645A (en)
CN (1) CN101370512A (en)
AU (1) AU2007207074B8 (en)
BR (1) BRPI0706541A2 (en)
CA (1) CA2637540A1 (en)
EA (1) EA200801670A1 (en)
WO (1) WO2007082742A1 (en)
ZA (1) ZA200807063B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007146785A2 (en) 2006-06-09 2007-12-21 Apple Inc. Touch screen liquid crystal display
RU2664631C1 (en) * 2017-05-25 2018-08-21 Федеральное государственное бюджетное военное образовательное учреждение высшего образования Военно-медицинская академия им. С.М. Кирова Министерства обороны Российской Федерации (ВМедА) Method of isolated hyperthermic chemoperfusion of the liver
RU2740570C1 (en) * 2020-03-05 2021-01-15 Федеральное государственное бюджетное военное образовательное учреждение высшего образования "Военно-медицинская академия имени С.М. Кирова" Министерства обороны Российской Федерации (ВМедА) Method for isolated fraction retrograde hepatic perfusion in experiment
RU2747908C1 (en) * 2020-03-05 2021-05-17 Федеральное государственное бюджетное военное образовательное учреждение высшего образования "Военно-медицинская академия имени С.М. Кирова" Министерства обороны Российской Федерации (ВМедА) Method for isolated shared porto-caval liver perfusion in experiment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19842415A1 (en) * 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmaceutical preparation for treating e.g. tumors, thrombosis or inflammation, contains cyclic pentapeptide integrin inhibitor and chemotherapeutic agent and/or angiogenesis inhibitor
WO2002055106A2 (en) * 2001-01-09 2002-07-18 Merck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
EP1381384B1 (en) * 2001-04-24 2011-05-25 Merck Patent GmbH COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha
EP1487492A4 (en) * 2002-03-04 2008-10-01 Medimmune Inc The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
AU2003276084B2 (en) * 2002-10-10 2009-07-09 Merck Patent Gmbh Bispecific anti-Erb-B antibodies and their use in tumor therapy

Also Published As

Publication number Publication date
EP1978991A1 (en) 2008-10-15
WO2007082742A1 (en) 2007-07-26
US20110165150A1 (en) 2011-07-07
JP2009525957A (en) 2009-07-16
EA200801670A1 (en) 2009-02-27
BRPI0706541A2 (en) 2011-03-29
KR20080089645A (en) 2008-10-07
AU2007207074B8 (en) 2013-01-31
CN101370512A (en) 2009-02-18
AU2007207074B2 (en) 2013-01-17
ZA200807063B (en) 2009-10-28
CA2637540A1 (en) 2007-07-26
AU2007207074A1 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
WO2007084670A3 (en) Specific therapy using integrin ligands for treating cancer
WO2008087025A3 (en) Specific therapy and medicament using integrin ligands for treating cancer
MXPA03010121A (en) Combination therapy using anti-egfr antibodies and anti-hormonal agents.
EP3241840A3 (en) Inhibition of axl signaling in anti-metastatic therapy
WO2010136168A3 (en) Continuous administration of cilengitide in cancer treatments
MX339142B (en) Combinations and modes of administration of therapeutic agents and combination therapy.
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
WO2002055106A3 (en) Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
MX2009009537A (en) Nanoparticle comprising rapamycin and albumin as anticancer agent.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX2020007130A (en) Methods of treating metastatic cancers using axl decoy receptors.
WO2007082742A8 (en) Isolated organ perfusion combination therapy of cancer
WO2005009363A3 (en) Treatment of pre-cancerous conditions and prevention of cancer using pcdgf-based therapies
WO2015038896A3 (en) Wilforlide a for overcoming chemotherapy resistance
WO2010057596A3 (en) New therapy and medicament using integrin ligands for treating cancer
HK1200354A1 (en) Combination therapy for chemoresistant cancers
WO2014115859A3 (en) Combination molecularly targeted drug for tumor therapy and prevention
WO2011094260A3 (en) Novel bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer
AR049135A1 (en) COMPOSITION, METHOD, KIT AND TREATMENT WITH OXALIPLATIN AND AN EGFR INHIBITOR, AS ERLOTINIB
WO2018231799A8 (en) Methods of treating brain tumors using combination therapy
WO2003072061A3 (en) Methods and compositions for treating gastrointestinal toxicity induced by cytoablative therapy
TW200501984A (en) A medicament for the two-step perioperative therapy of solid tumours
WO2006124573A3 (en) Treatment of cancer with 2-deoxyglucose
WO2007047489A3 (en) Compositions and methods for use in cancer therapy
WO2014035828A3 (en) Inhibition of axl signaling in anti-metastatic therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007702856

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/009040

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2637540

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200780002542.0

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2008550686

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 200801670

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2007207074

Country of ref document: AU

Ref document number: 3337/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020087020190

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2007207074

Country of ref document: AU

Date of ref document: 20070118

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0706541

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080715